Stock listing
NASDAQ:LOGC LogicBio Therapeutics Inc Stock
Follow LogicBio Therapeutics Inc into a list and get an email when it puts out news.
Delisted NASDAQ:LOGC no longer trades. Its last trading date is unknown. Company history and updates stay available on this page.
- Ticker
- NASDAQ:LOGC
- Asset type
- Stock
- Exchange
- NASDAQ
- Currency
- USD
LogicBio Therapeutics Inc on 6ix
- Decks
- 1 deck · latest Jan 12, 2021
Events
| Quarter | Results | Share move |
|---|---|---|
| Quarter to Sep 30, 2026 | Nov 10, 2026 | +0.3% |
| Quarter to Jun 30, 2026 | Aug 14, 2026 | +6.6% |
| Quarter to Mar 31, 2026 | May 15, 2026 | +1.1% |
| Quarter to Dec 31, 2025 | Mar 6, 2026 | +1.5% |
| Quarter to Sep 30, 2025 | Oct 28, 2025 | +1.6% |
| Quarter to Jun 30, 2025 | Aug 7, 2025 · After close | −1.2% |
| Quarter to Mar 31, 2025 | May 9, 2025 · After close | +2.6% |
| Quarter to Dec 31, 2024 | Mar 3, 2025 · Before open | −7.8% |
| Quarter to Sep 30, 2024 | Nov 7, 2024 · After close | +1.4% |
| Quarter to Jun 30, 2024 | Aug 8, 2024 · After close | −0.6% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Quarter to Mar 31, 2024 | May 8, 2024 · After close | −2.3% |
| Quarter to Dec 31, 2023 | Mar 4, 2024 · After close | −1.7% |
| Quarter to Sep 30, 2023 | Nov 7, 2023 · After close | +25.1% |
| Quarter to Jun 30, 2023 | Aug 3, 2023 · After close | −25.5% |
| Quarter to Mar 31, 2023 | May 4, 2023 · After close | −2.1% |
| Quarter to Dec 31, 2022 | Feb 23, 2023 · After close | −28.7% |
| Quarter to Sep 30, 2022 | Nov 9, 2022 · After close | +15.3% |
| Quarter to Jun 30, 2022 | Aug 9, 2022 · After close | +1.2% |
| Quarter to Mar 31, 2022 | May 5, 2022 · After close | −5.3% |
| Quarter to Dec 31, 2021 | Mar 1, 2022 · After close | −5.7% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (January 2021) | Investor deck | 43 slides | Jan 12, 2021 |
Cap table
Built by 6ix from LogicBio Therapeutics Inc’s releases · as of Jul 31, 2026
- Common shares
- 45,753,716
- Fully diluted
- 45,753,716
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 45,753,716 | Jul 31, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Jul 31, 2026 | 45,753,716 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Mark Enyedy Other companies: Charles River Laboratories International, Inc. (Director · Since at least May 20, 2025); BioMarin Pharmaceutical Inc. (Director · Since at least Dec 27, 2023); Akebia Therapeutics, Inc. (Director · Dec 12, 2018 – Jun 5, 2020 · Past); Keryx Biopharmaceuticals Inc (Director · Jun 30, 2018 – Dec 12, 2018 · Past); ImmunoGen Inc (CHIEF EXECUTIVE OFFICER, Director · Feb 15, 2018 – Feb 12, 2024 · Past) | Director · Mar 17, 2020 – Nov 16, 2022 · Past |
| Daphne Karydas Other companies: COMPASS Pathways Plc (Director · Since at least Sep 18, 2023); Mineralys Therapeutics, Inc. (Director · Since at least Sep 13, 2023); Syndax Pharmaceuticals, Inc. (Chief Financial Officer · Feb 3, 2021 – Feb 3, 2021 · Past); Eucrates Biomedical Acquisition Corp. (Director · Oct 23, 2020 – Oct 23, 2020 · Past) | Director · Dec 10, 2020 – Nov 16, 2022 · Past |
| Tomer Kariv Other companies: Keros Therapeutics, Inc. (Director · Since at least Apr 7, 2020); 89bio Inc (Director · Nov 8, 2019 – Nov 11, 2019 · Past); VBI Vaccines Inc. (Director · Jan 23, 2018 – Jan 31, 2019 · Past); Arno Therapeutics Inc (Director · Jan 12, 2016 – Sep 8, 2016 · Past) | Director · Oct 18, 2018 – Dec 19, 2019 · Past |
| Jeff Goater Other companies: Vaccinex, Inc. (Director · Aug 9, 2018 – May 11, 2021 · Past); Surface Oncology Inc (Director · Apr 18, 2018 – Sep 8, 2023 · Past) | Director · Dec 10, 2020 – Nov 16, 2022 · Past |
| Leon Chen Other companies: Eikon Therapeutics, Inc. (Director · Since at least Feb 4, 2026); Nurix Therapeutics, Inc. (Director · Jul 23, 2020 – May 6, 2021 · Past) | Director · Oct 18, 2018 – Nov 16, 2022 · Past |
| Seokho Bryan Yoon Other companies: Terns Pharmaceuticals, Inc. (COO and General Counsel · Feb 4, 2021 – May 31, 2024 · Past); Nightstar Therapeutics PLC (General Counsel and Secretary · Jan 1, 2019 – Jun 6, 2019 · Past) | Chief Admin Officer & GC · Nov 11, 2019 – Apr 15, 2020 · Past |
| Cecilia Jones Other companies: Agios Pharmaceuticals, Inc. (Chief Financial Officer · Since at least Sep 26, 2022) | Chief Financial Officer · Jan 11, 2021 – Mar 1, 2022 · Past |
| Richard A Moscicki Other companies: Akcea Therapeutics Inc (Director · Jun 1, 2018 – Jun 14, 2019 · Past) | Director · Oct 18, 2018 – Nov 16, 2022 · Past |
| Daniel Gruskin | Chief Medical Officer · May 19, 2021 – Nov 16, 2022 · Past |
| Kenneth Huttner | SVP, Head of Clinical Dev. · Feb 20, 2019 – Feb 11, 2020 · Past |
All 11 people
| Person | Seat |
|---|---|
| Matthias Jaffe | Chief Financial Officer · Oct 18, 2018 – Apr 15, 2020 · Past |
Log in to ask 6ix AI your own questions about LogicBio Therapeutics Inc.